The latest venture capital, seed, and angel deals for NYC startups for 2/8/19 featuring funding details for HiberCell and Axon Therapies – a busy date in the healthcare/biotech space. This page will be updated throughout the day to reflect any new fundings.
HiberCell — $60.8M
HiberCell, the biotech company focused on preventing relapse and metastasis of cancer by focusing on dormant tumors, has raised $60.8M in funding from investors that include ARCH Venture Partners, Hillhouse Capital Group, Celgene, 6 Dimensions Capital, and Life Sciences Fund Amsterdam.
Axon Therapies — $7.5M
Axon Therapies, the makers of device that uses neuromodulation to treat heart failure, has raised $7.5M in funding according to a recent SEC filing. The filing indicates that the total offering is for $15M and there were ten participants in this close. Axon was founded by Howard R. Levin and Mark Gelfand in 2014 and had previously raised $1.3M in funding in 2017.
